Adaptimmune Therapeutics PLC (ADAP) Receives Consensus Rating of “Buy” from Brokerages
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has received an average rating of “Buy” from the six analysts that are covering the firm. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $15.67.
A number of analysts have weighed in on the company. Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a report on Tuesday, July 12th. Raymond James Financial Inc. assumed coverage on Adaptimmune Therapeutics PLC in a report on Friday, September 30th. They set an “outperform” rating and a $16.00 price target for the company.
Several hedge funds have recently modified their holdings of the stock. Glenmede Trust Co. NA increased its stake in shares of Adaptimmune Therapeutics PLC by 574.9% in the second quarter. Glenmede Trust Co. NA now owns 20,923 shares of the company’s stock valued at $170,000 after buying an additional 17,823 shares in the last quarter. Springbok Capital Management LLC acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter valued at $202,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Adaptimmune Therapeutics PLC by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock valued at $888,000 after buying an additional 3,519 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Adaptimmune Therapeutics PLC by 286.3% in the first quarter. Renaissance Technologies LLC now owns 113,200 shares of the company’s stock valued at $920,000 after buying an additional 83,900 shares during the last quarter. Finally, New Leaf Venture Partners L.L.C. acquired a new position in shares of Adaptimmune Therapeutics PLC during the second quarter valued at $1,035,000. Institutional investors own 45.11% of the company’s stock.
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded up 0.57% during trading on Wednesday, reaching $5.28. The company’s stock had a trading volume of 124,648 shares. The firm’s market cap is $373.74 million. The stock’s 50 day moving average price is $6.83 and its 200-day moving average price is $8.33. Adaptimmune Therapeutics PLC has a 12 month low of $5.10 and a 12 month high of $14.78.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.16. Adaptimmune Therapeutics PLC had a negative return on equity of 21.36% and a negative net margin of 427.33%. Equities analysts predict that Adaptimmune Therapeutics PLC will post ($1.09) EPS for the current year.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.